



Cite this: *Chem. Commun.*, 2022, 58, 5359

Received 22nd February 2022,
Accepted 1st April 2022

DOI: 10.1039/d2cc01090a

rsc.li/chemcomm

Unearthing the unique stability of thiophosphonium-C-terminal cysteine adducts on peptides and proteins†

Richard J. Spears,  Alina Chrzastek,  Steven Y. Yap,  Kersti Karu, Abil E. Aliev, James R. Baker * and Vijay Chudasama *

Herein we report a fundamental discovery on the use of tris(dialkylamino)phosphine reagents for peptide and protein modification. We discovered that C-terminal thiophosphonium species, which are uniquely stable, could be selectively and rapidly generated from their disulfide counterparts. In sharp and direct contrast, internal thiophosphonium species rapidly degrade to dehydroalanine. We demonstrate this remarkable chemoselectivity on a bis-cysteine model peptide, and the formation of a stable C-terminal-thiophosphonium adduct on an antibody fragment, as well as characterise the species in various small molecule/peptide studies.

Protein modification has established itself as a cornerstone of chemical biology over the past two decades.^{1,2} Applications of this field are wide ranging; examples include design of imaging agents³ and novel therapeutics such as antibody–drug conjugates (ADCs).⁴ Typically, protein modification occurs at an amino acid side chain, such as lysine⁵ or tyrosine.^{6,7} Cysteine in particular is regularly used due to the suitability of its thiol side chain^{8–11} (ease of incorporation *via* conventional site-directed mutagenesis, high nucleophilicity at neutral pH, low natural abundance which assists in avoiding heterogeneity).¹² In addition to side chain modification, the N-terminus is frequently used for site-specific modification due to the unique properties of the α -amino group compared to those of the ϵ -amino groups of lysine residues (*e.g.* pK_a 6–8 vs. pK_a ca. 10).¹³ Occasionally, strategies targeting the N-terminus use both the α -amino group and amino acid side chain, as seen for N-terminal cysteine modification using cyanobenzothiazole derivatives.^{14,15} In contrast to the N-terminus or side chains, examples of chemical modification specific to the C-terminus are comparatively rare; enzymatic-based strategies tend to dominate this area of research.¹⁶ This is logical given the

challenge of both activating and selectively targeting the carboxylic acid group of the C-terminus in the presence of glutamate and aspartate carboxylic acid side chains. Currently, the only two examples reported in the literature of chemical bioconjugation specific for proteins bearing canonical amino acid residues at the C-terminus include (i) an N \rightarrow S acyl transfer of C-terminal cysteines to generate thioesters, which can be converted to hydrazides using subsequent native chemical ligation (NCL)¹⁷ and (ii) photoredox-mediated decarboxylative addition of Michael acceptors to the C-terminus, which selectively targets the C-terminus carboxylate over glutamate/aspartic acid carboxylates through differences in oxidative potentials.¹⁸ We therefore hypothesised that investigating protein modification strategies focused on the C-terminus would be of high value. In particular, we envisaged that potential modifications specifically on the C-terminus side chain could be “locked” into place by the adjacent carboxylic acid (akin to that of the α -amino group of the N-terminus for N-terminal modifications). We decided to focus on C-terminal cysteine, given cysteine’s aforementioned favourable properties, anticipating that a modification strategy for a C-terminal cysteine may have a different outcome compared to modification of cysteine residues at internal positions within an amino acid sequence. Moreover, several peptides and proteins (*e.g.* the majority of therapeutic full antibodies)¹⁹ contain a natural C-terminal cysteine residue.

During our investigation of chemical modification strategies focused at the C-terminus, our attention was turned towards tris(dialkylamino)phosphines. These reagents, specifically tris(dimethylamino)phosphine/hexamethylphosphorous triamide, (HMPT **1**), have previously been reported for use in activation of alkyl thiols towards nucleophilic displacement reactions in organic synthesis,²⁰ desulfurization reactions^{21,22} and in formation of dehydroalanine (Dha) on small molecules and proteins.²³ All of the aforementioned transformations proceed *via* a thiophosphonium intermediate, which are traditionally regarded as highly reactive and difficult to isolate.²⁴ In

UCL Department of Chemistry, 20 Gordon Street, London WC1H 0AJ, UK.

E-mail: v.chudasama@ucl.ac.uk, j.r.baker@ucl.ac.uk

† Electronic supplementary information (ESI) available. See <https://doi.org/10.1039/d2cc01090a>



some specific cases, however, the thiophosphonium intermediate has been isolated either as a small molecule salt²⁰ or stabilised through use of rotaxanes,²⁴ or observed by LCMS upon treating a disulfide containing protein with HMPT **1**.²³ We were particularly intrigued how the thiophosphonium motif might behave when located at the C-terminus near the carboxylate group, and whether or not the presence of a nearby carboxylate may (i) impart stabilising interactions between the thiophosphonium cation and carboxylate, (ii) affect propensity of thiophosphonium species towards nucleophilic attack/desulfurisation, and (iii) affect the pK_a of the cysteine α proton, and therefore affect the likelihood of the thiophosphonium decomposition to give Dha.

To begin with, we reacted *N*-acetyl cysteine **2** with 4-nitrophenyl disulfide **3** to synthesise model *N*-acetyl cysteine disulfide **4** for use in validation of thiophosphonium formation. We chose to use unsymmetrical alkyl-aryl disulfides (S-SAr) as these have previously been reported to assist in facilitating regioselective phosphine attack at the alkyl sulfur of the S-SAr disulfide,²⁵ generating the desired thiophosphonium species. We initially screened a panel of commercially available phosphine reagents **1** and **5–11** against disulfide **4** in MeOH, and analysed formation of thiophosphonium by LCMS analysis (Fig. 1a). Tris(dialkylamino)phosphines **1**, **5**, **6**, and **7** all gave rise to thiophosphonium cations **12–15** (respectively) as judged by LCMS. Minor thiophosphonium formation was noted in the case of mixed *N*-*O*-phosphine **8** to give **16**, whereas no thiophosphonium species **17–19** was detected when using mixed *N*-*O*-phosphine **9** and alkyl phosphines tris(2-carboxyethyl)phosphine (TCEP) **10** and tris(hydroxypropyl)phosphine (THPP) **11**. We next sought to see if one of these thiophosphonium species could both be formed in aqueous conditions and isolated for characterisation. We chose thiophosphonium **12** for this purpose, as HMPT **1** has been reported before for formation of thiophosphonium intermediates. We found that thiophosphonium **12** could additionally be formed under aqueous conditions in H₂O:MeCN (1:1) as judged by LCMS and

subsequently purified by semi-preparative high-pressure liquid chromatography (HPLC) in a 52% yield. ³¹P NMR of **12** revealed a single peak at δ 65.6 ppm, which was in accordance with previously reported ³¹P NMR data for thiophosphonium salts derived from HMPT **1**.²⁶ Thiophosphonium **12** formation was further confirmed *via* tandem mass spectrometry (MSMS), with a fragment corresponding to the thiophosphonium motif as the major species following MS¹ (Fig. 1b). Thiophosphonium **12** proved resistant to decomposition when incubated in 0.2 M PB pH 8 buffer for 18 h and, in buffer, proved inert towards nucleophiles previously reported to facilitate nucleophilic displacement of the thiophosphonium group (see ESI†).²⁰ Thiophosphonium **12** also proved to be completely resistant to strongly acidic conditions (10 mM HCl, 18 h, 37 °C), with only partial decomposition of the thiophosphonium motif observed under strongly basic conditions (10 mM NaOH, 18 h, 37 °C, see ESI†).

Next, thiophosphonium formation on small peptide units was investigated using HMPT **1**. Peptides FEKGC **20**, FCEKG **21** and CFEKG **22** (containing cysteine at the C-terminus, at an internal position and at the N-terminus respectively) were synthesised *via* solid phase peptide synthesis (SPPS) and subsequently derivatised with Ellman's reagent **23** to give the corresponding disulfide-containing peptides **24** (C-terminal), **25** (internal) and **26** (N-terminal, Fig. 2, see ESI† for full details). To begin with, peptide **24** was subjected to HMPT **1** in PB pH 8.0 (10% MeCN) at 37 °C, and the results were analysed by LCMS. Full conversion to thiophosphonium peptide species **27** (Fig. 3a) was clearly observed at t = 5 min (as judged by LCMS, see ESI†). We additionally saw formation of a previously reported SAR thiophosphonium species (see ESI†).²³ Thiophosphonium species **27** exhibited stability during incubation at 37 °C at t = 1 h and t = 18 h (see ESI†) and MSMS analysis further confirmed the thiophosphonium as being located on the C-terminus. We next treated peptide **25** with HMPT **1**. Initially, this resulted in thiophosphonium **28** formation at t = 5 min (see ESI†); in contrast to thiophosphonium **27**,




Fig. 1 (a) Formation of thiophosphonium species and detection by LCMS (b) synthesis of thiophosphonium **12** and ³¹P NMR and MSMS data for isolated **12**.




Fig. 2 Cysteine-containing peptides and their disulfide-containing counterparts.

however, thiophosphonium **28** had almost completely degraded at $t = 1$ h (as observed by LCMS, see ESI[†]). We hypothesised, in accordance with previous literature, decomposition of the thiophosphonium species to Dha to give peptide **29** was occurring following HMPT **1** addition (Fig. 3b). Although Dha peptide **29** could not be reliably observed in LCMS analysis, Dha formation was confirmed through thiol addition of *n*-hexanethiol **30** to the reaction mixture of peptide **28** and HMPT **1** to give thiol-capped peptide **31**, suggesting Dha **29** as the intermediate resulting from thiophosphonium degradation (see ESI[†]). Finally, we treated peptide **26** with HMPT **1**. Thiophosphonium **32** formation was observed, with some degradation after 18 h of incubation observed *via* LCMS (see ESI[†]). We observed a peak in the LCMS trace which could have

corresponded to the associated Dha peptide or ketone-containing peptide **33**, which could have formed through degradation of thiophosphonium **32** to the corresponding Dha/enamine-containing peptide, followed by tautomerisation to an imine and finally hydrolysis to the corresponding ketone **33**. Addition of *n*-hexanethiol **30** to the reaction mixture gave no reaction as observed *via* LCMS, whilst addition of benzyloxamine **34** under slightly acidic conditions gave a new peak in the LCMS trace corresponding to oxime product **35** (see ESI[†]). We thus hypothesised that the peak corresponded to ketone-containing peptide **33**.

To further demonstrate this difference in reactivity, we next turned our attention towards the model peptide FCEKAGC **36**, which contains two cysteine residues; Cys2 at an internal position and Cys7 at the C-terminus of the peptide. Following derivatisation of the thiol groups with Ellman's reagent **23** to give peptide **37**, the peptide was then treated with HMPT **1** to generate Dha at position 2 and a thiophosphonium adduct at position 7 (peptide **38**). Further treatment with *n*-hexanethiol **30** subsequently gave dually modified peptide **39** (Fig. 4a), which was isolated as two diastereoisomers by preparative-HPLC and confirmed by LCMS and MSMS analysis (Fig. 4b).

Finally, as a proof of concept we tested HMPT **1** within the context of modifying a protein containing a C-terminal cysteine. Specifically, we focused on modifying the C-terminal cysteine of the light chain of the herceptin (Trastuzumab) Fab fragment. Initially, reduction of the Fab disulfide bond and capping of the majority of the heavy chain free thiol only was performed (see ESI[†] for details), *i.e.* to give the free thiol light chain and thiol-capped heavy chain as the major products. The Fab light chain free thiol was then derivatised with Ellman's reagent




Fig. 3 (a) Reaction of peptide **24** with HMPT **1** to give the stable C-terminal thiophosphonium **27** as confirmed by LCMS and MSMS analysis. (b) Reaction of peptide **25** with HMPT **1** to give internal thiophosphonium **28**, which rapidly degrades to Dha **29**, which can be modified with *n*-hexanethiol **30** to give peptide **31**. (c) Reaction of peptide **26** with HMPT **1** to give N-terminal thiophosphonium **32** as a major product and ketone **33** as a minor product. Ketone **33** can be functionalised with aminooxy **34** to give oxime product **35**.






Fig. 4 (a) Dual modification of peptide **36** to give dually modified peptide **39**, with confirmation by LCMS analysis and purification by HPLC. (b) MSMS analysis of **39**.

to give the corresponding light chain aryl thiol disulfide. This was subsequently treated with HMPT **1**, which generated the thiophosphonium species with complete conversion from the Elman's capped light chain. LCMS analysis confirmed the presence of the Fab light chain thiophosphonium, with no decomposition to Dha observed (see ESI† for details).

To conclude, we have demonstrated the synthesis of a thiophosphonium species based on *N*-acetyl cysteine, along with C-terminal cysteine-containing peptides and trastuzumab Fab light chain. These thiophosphonium species displayed unexpected stability and could be subsequently isolated and analysed by NMR and/or MS. In contrast, thiophosphonium formation at a cysteine positioned internally within a peptide sequence resulted in rapid decomposition of the C-terminal thiophosphonium, either through ionic interactions between the carboxylic acid and thiophosphonium, or through a reduced propensity for abstraction of the alpha proton and subsequent collapse of the thiophosphonium species to Dha. We intend to explore this difference in reactivity of C-terminal and internal cysteines for further development of protein modification strategies in future work, but share our current findings here in view of the high impact of this fundamental discovery.

We gratefully acknowledge the Leverhulme Trust (RPG-2017-288, RPG-2020-010) and EPSRC (EP/T016043/1) for funding.

Conflicts of interest

V. C. and J. R. B. are Directors of the spin-out ThioLogics, but there are no competing financial interests to declare.

References

- 1 C. D. Spicer and B. G. Davis, *Nat. Commun.*, 2014, **5**, 4740.
- 2 E. A. Hoyt, P. M. S. D. Cal, B. L. Oliveira and G. J. L. Bernardes, *Nat. Rev. Chem.*, 2019, **3**, 147–171.
- 3 P. Agarwal, B. J. Beahm, P. Shieh and C. R. Bertozzi, *Angew. Chem., Int. Ed.*, 2015, **54**, 11504–11510.
- 4 S. J. Walsh, J. D. Bargh, F. M. Dannheim, A. R. Hanby, H. Seki, A. J. Counsell, X. Ou, E. Fowler, N. Ashman, Y. Takada, A. Isidro-Llobet, J. S. Parker, J. S. Carroll and D. R. Spring, *Chem. Soc. Rev.*, 2021, **50**, 1305–1353.
- 5 M. J. Matos, B. L. Oliveira, N. Martínez-Sáez, A. Guerreiro, P. M. S. D. S. D. Cal, J. Bertoldo, M. Maneiro, E. Perkins, J. Howard, M. J. Deery, J. M. Chalker, F. Corzana, G. Jiménez-Osés and G. J. L. Bernardes, *J. Am. Chem. Soc.*, 2018, **140**, 4004–4017.
- 6 D. Alvarez Dorta, D. Deniaud, M. Mével and S. G. Gouin, *Chem. – Eur. J.*, 2020, **26**, 14257–14269.
- 7 P. A. Sziij, K. A. Kostadinova, R. J. Spears and V. Chudasama, *Org. Biomol. Chem.*, 2020, **18**, 9018–9028.
- 8 C. Zhang, M. Welborn, T. Zhu, N. J. Yang, M. S. Santos, T. Van Voorhis and B. L. Pentelute, *Nat. Chem.*, 2016, **8**, 120–128.
- 9 C. Bahou, D. A. Richards, A. Maruani, E. A. Love, F. Javaid, S. Caddick, J. R. Baker and V. Chudasama, *Org. Biomol. Chem.*, 2018, **16**, 1359–1366.
- 10 M. A. Kasper, M. Glanz, A. Stengl, M. Penkert, S. Klenk, T. Sauer, D. Schumacher, J. Helma, E. Krause, M. C. Cardoso, H. Leonhardt and C. P. R. Hackenberger, *Angew. Chem., Int. Ed.*, 2019, **58**, 11625–11630.
- 11 E. Gil de Montes, A. Istrate, C. D. Navo, E. Jiménez-Moreno, E. A. Hoyt, F. Corzana, I. Robina, G. Jiménez-Osés, A. J. Moreno-Vargas and G. J. L. Bernardes, *Angew. Chem., Int. Ed.*, 2020, **59**, 6196–6200.
- 12 O. Koniev and A. Wagner, *Chem. Soc. Rev.*, 2015, **44**, 5495–5551.
- 13 C. B. Rosen and M. B. Francis, *Nat. Chem. Biol.*, 2017, **13**, 697–705.
- 14 L. Cui and J. Rao, *Methods Mol. Biol.*, 2015, **1266**, 81–92.
- 15 H. Ren, F. Xiao, K. Zhan, Y. P. Kim, H. Xie, Z. Xia and J. Rao, *Angew. Chem., Int. Ed.*, 2009, **48**, 9658–9662.
- 16 Y. Zhang, K. Y. Park, K. F. Suazo and M. D. Distefano, *Chem. Soc. Rev.*, 2018, **47**, 9106–9136.
- 17 A. L. Adams, B. Cowper, R. E. Morgan, B. Premjee, S. Caddick and D. Macmillan, *Angew. Chem., Int. Ed.*, 2013, **52**, 13062–13066.
- 18 S. Bloom, C. Liu, D. K. Kölmel, J. X. Qiao, Y. Zhang, M. A. Poss, W. R. Ewing and D. W. C. C. MacMillan, *Nat. Chem.*, 2018, **10**, 205–211.
- 19 Y. Shen, L. Zeng, A. Zhu, T. Blanc, D. Patel, A. Pennello, A. Bari, S. Ng, K. Persaud, Y. K. Kang, P. Balderes, D. Surguladze, S. Hindi, Q. Zhou, D. L. Ludwig and M. Snavely, *MABs*, 2013, **5**, 418–431.
- 20 G. A. Krafft and T. L. Siddall, *Tetrahedron Lett.*, 1985, **26**, 4867–4870.
- 21 G. J. L. Bernardes, E. J. Grayson, S. Thompson, J. M. Chalker, J. C. Errey, F. El Oualid, T. D. W. Claridge and B. G. Davis, *Angew. Chem., Int. Ed.*, 2008, **47**, 2244–2247.
- 22 M. S. Collins, M. E. Carnes, B. P. Nell, L. N. Zakharov and D. W. Johnson, *Nat. Commun.*, 2016, **7**, 11052.
- 23 J. M. Chalker, S. B. Gunnoo, O. Boutureira, S. C. Gerstberger, M. Fernández-González, G. J. L. Bernardes, L. Griffin, H. Hailu, C. J. Schofield and B. G. Davis, *Chem. Sci.*, 2011, **2**, 1666–1676.
- 24 T. Oku, Y. Furusho and T. Takata, *Org. Lett.*, 2003, **5**, 4923–4925.
- 25 D. N. Harpp and J. G. Gleason, *J. Org. Chem.*, 1971, **36**, 73–80.
- 26 R. K. Haynes and C. Indorato, *Aust. J. Chem.*, 1984, **37**, 1183–1194.

